A randomised, open-label phase II study evaluating the efficacy and safety of folfox6 + cetuximab as first-line therapy in patients with metastatic colorectal cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cetuximab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Cancer metastases; Colorectal cancer
- Focus Therapeutic Use
- 01 May 2012 Biomarkers information updated
- 22 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jun 2009 A post-study survival update was presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Merck Serono media release.